A Study of CT-388 in Otherwise Healthy Overweight and Obese Adults and Patients with Type 2 Diabetes Mellitus
Launched by CARMOT THERAPEUTICS, INC. · Apr 6, 2021
Trial Information
Current as of June 19, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Males or females
- • 18-65 years old, inclusive
- • BMI 27.0-40.0, inclusive
- • Stable body weight for 2 months
- Exclusion Criteria:
- • Significant medical history
- • Uncontrolled hypertension
- • History of malignancy
About Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for a range of diseases through its proprietary drug discovery platform. Leveraging advanced chemistry and machine learning, Carmot aims to accelerate the identification and optimization of small molecules that target critical pathways in oncology and other therapeutic areas. Committed to advancing healthcare, the company collaborates with leading academic institutions and industry partners to translate scientific discoveries into novel treatments, ultimately enhancing patient outcomes and addressing unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Adelaide, South Australia, Australia
Perth, Western Australia, Australia
Monterrey, Nuevo Leon, Mexico
Monterrey, Nuevo Leon, Mexico
Patients applied
Trial Officials
Clinical Trials
Study Director
Carmot Therapeutics, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials